Molecular cloning and pharmacological characterization of serotonin 5-HT3A receptor subtype in dog

    loading  Checking for direct PDF access through Ovid

Abstract

In order to establish if the canine 5-hydroxytryptamine type 3A (5-HT3A) receptors share the pharmacological profile with human 5-HT3A receptors, we cloned and performed a molecular pharmacological characterization of the canine 5-HT3A receptor. The 5-HT3A cDNA was cloned from canine brain by polymerase chain reaction amplification. It encodes a 483 amino acid peptide that exhibits from 80% (mice) to 90% (ferrets) identity to other sequenced mammalian 5-HT3A receptors. The receptor agonists 5-hydroxytryptamine (5-HT) and meta-chlorophenylbiguanide (mCPBG) showed little differences between the two species, whereas 2-methyl-5-hydroxytryptamine (2-Me-5-HT) was ten times weaker at canine receptors than at human receptors. The potencies at the canine 5-HT3 receptors were 9.9 μM (5-HT), 79 μM (2-Me-5-HT) and 0.8 μM (mCPBG). The selective, competitive receptor antagonist ondansetron was ten times more potent at human receptors compared to canine receptors (Kb = 0.9 nM), while (+)-tubocurarine was 1000-fold more potent at canine receptors (Kb = 3.0 nM) than at human receptors. Examination of the presumed ligand binding extracellular domain revealed one residue, where the canine receptor differs from all previously characterized 5-HT3A receptors, i.e. other species contain a conserved Trp195, whereas the canine orthologue contains a Leu195. To address the differences in potencies at the human and canine 5-HT3A receptors seen in this study, we introduced a L195W point mutation in the canine orthologue. Data showed that the 195 residue can affect receptor agonist potency and efficacy as well as antagonist potency, but did produce a pharmacological profile identical to the human orthologue. We therefore conclude that position 195 is strongly involved in the receptor–ligand interaction, but additional residues must contribute to the overall pharmacological profile.

Related Topics

    loading  Loading Related Articles